Autumn Zuckerman, PharmD
A tailored clinical monitoring schedule that focused on oral oncolytics with high rates of adverse events (AEs) slashed treatment interruptions by more than 50% and significantly reduced medication-related hospitalizations, according to a new study by specialty pharmacists from Vanderbilt University Medical Center, in Nashville, Tenn.
“We are focused on looking at oral oncolytics individually by medication,” explained Autumn Zuckerman, PharmD,